Publications by authors named "Laura Cisar"

Claim this Profile
R
Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.
Sandy Srinivas, Dara Stein, Dana Y Teltsch, Sunning Tao, Laura Cisar

J Oncol Pharm Pract· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.
Brian I Rini, Victor Gruenwald, Eric Jonasch, Mayer N Fishman, Yoshihiko Tomita, Laura Cisar

Target Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.
Thomas E Hutson, Xiaolong Jiao, Thomas Wilson, Laura Cisar, Elizabeth A MacLean

Future Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
Elizabeth MacLean, Jack Mardekian, Laura A Cisar, Caroline J Hoang, James Harnett

J Manag Care Spec Pharm· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
Elizabeth MacLean, Laura Cisar, Kimberly Mehle, Daria Eremina, Jane M Quigley

J Manag Care Spec Pharm· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Brian I Rini, David I Quinn, Michael Baum, Laura S Wood, Jamal Tarazi, Laura Cisar

Target Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Jacques Grill, Birgit Geoerger, Lyle Gesner, Danuta Perek, Pierre Leblond, Laura Cisar

Neuro Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
Darren Hargrave, Birgit Geoerger, Didier Frappaz, Torsten Pietsch, Lyle Gesner, Laura Cisar

J Neurooncol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Arnaud D Roth, Mauro Delorenzi, Sabine Tejpar, Pu Yan, Dirk Klingbiel, Laura Cisar

J Natl Cancer Inst· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Judith M Bliss, Lucy S Kilburn, Robert E Coleman, John F Forbes, Alan S Coates, Laura Cisar

J Clin Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Arnaud D Roth, Sabine Tejpar, Mauro Delorenzi, Pu Yan, Roberto Fiocca, Laura Cisar

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Eric Van Cutsem, Roberto Labianca, György Bodoky, Carlo Barone, Enrique Aranda, Laura Cisar

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.
Luis Parodi, Eve Pickering, Laura A Cisar, Doug Lee, Raoudha Soufi-Mahjoubi

Arch Drug Inf· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
Gilles Vassal, Francesco Giammarile, Mariel Brooks, Birgit Geoerger, Dominique Couanet, Laura Cisar

Eur J Cancer· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
Gilles Vassal, Dominique Couanet, Elizabeth Stockdale, Anne Geoffray, Birgit Geoerger, Laura Cisar

J Clin Oncol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Larry J Schaaf, Lisa A Hammond, Stuart J Tipping, Richard M Goldberg, Rakesh Goel, Laura A Cisar

Clin Cancer Res· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Caio M Rocha Lima, Mark R Green, Robert Rotche, Wilson H Miller, G Mark Jeffrey, Laura A Cisar

J Clin Oncol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.
Gary Hudes, Naomi Haas, Gwen Yeslow, Thomas Gillon, Per Olov Gunnarsson, Laura Cisar

J Clin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis